Well, Brian, we are quite confident about the healthcare business. As Alan has mentioned, just keep in mind, we’ve said it before, it’s the highest margin business. We are investing heavily, continue to do that for R&D for the new platform that we’re developing, which we have said before that it’s going to change our whole platform. It’s going to take a couple of years to do it. In the meantime, we remain confident and for the disappointing Q3 specifically, especially when you also compare it with the COVID related previous, what I call it, tailwinds. But at the same time, and maybe Alan can comment on it, this quarter, Q3, we were expecting some significant size contracts, which got delayed. We are told that imminently will happen. So, that we believe also normally seasonally, Q4 is stronger than Q3 anyway. The Q4 will be a stronger quarter for it. And we are quite confident. And keep in mind that we have bought PeraHealth a couple of quarters ago, we bought SafeNSound, we believe in that platform. We are looking at it in the connectivity story, besides patient monitoring, we are looking at cardiology. We are trying to make it a services company in a way in some products. So all-in-all, we are quite excited about it. And as we have said it before, yes, it’s disappointing. It’s a book and ship into it, so that as these contracts get delayed, it changes from one quarter to the other. But with the margin it is, with the connectivity that we are looking at, with the new change we have made in the sales management team of North America, we are very confident of the future of Spacelabs. Alan, do you want to add something?